FSS Breaks Ground on Major 503B Outsourcing Facility Expansion in Wichita, KS

Fagron Sterile Services US Breaks Ground on Major 503B Outsourcing Facility Expansion to Support Increased Demand for Critical Medications

WICHITA, KS - MAY 23, 2024 - Fagron Sterile Services US (FSS), a leading 503B outsourcing partner to patient-focused healthcare facilities, proudly announced another groundbreaking, the first this year coming back in March (read more).

In addition to a new state-of-the-art quality testing lab, FSS announced a major expansion at their Wichita, KS 503B outsourcing campus (FSS has a second facility in Boston). The event, attended by state and local representative, including Mayor Lily Wu, FSS leadership and staff, marked the beginning of a project aimed at enhancing FSS's manufacturing capabilities and increasing production capacity.

The facility expansion project involves a 40% increase in square-footage to the existing facility. The project is designed to optimize process flows, increase operational efficiencies, and enhance compliance, supporting increased demand for FSS to provide high-quality sterile medications to healthcare providers across the nation. Additionally, the installation of roof-mounted solar panels will contribute to Fagron’s sustainability goals by helping offset electricity costs.

"Breaking ground on this facility expansion represents another major milestone for Fagron and our partnership with the city of Wichita," said Andrew Pulido, President, Fagron North America. “This expansion will considerably enhance our manufacturing capabilities, supporting a reliable supply of high-quality, ready-to-administer sterile medications, and advancing patient safety in communities nationwide.”

The expansion will also bring dozens of new STEM jobs to Wichita, supporting the city’s growth and development in the science, technology, engineering, and mathematics sectors.

“Our team’s dedication continues to make FSS a top employer in Wichita, driving innovation and excellence,” said Jason McGuire, SVP of Operations, FSS. “This expansion is not just about increasing our capacity; it’s about continuing to provide new opportunities for the community and reaffirming our commitment to quality and innovation.”

“FSS plays a crucial role in supporting a consistent supply of essential medications, especially amid ongoing drug shortages,” emphasized Ray Dixon, SVP of Commercial Operations at FSS. “The continued investment in operations underscores our dedication to supporting and enhancing patient care through reliable, high-quality medications.”

Mayor Lily Wu expressed her enthusiasm for the project, highlighting its importance for Wichita’s growth and development.

"The second groundbreaking in just a few months for FSS’ Wichita campus is another example of the thriving progress in Wichita’s industrial and healthcare sectors. The new facilities will continue bringing advanced technology and skilled jobs to our city," said Mayor Wu. "Fagron's commitment to expanding their operations here demonstrates their dedication to improving healthcare outcomes and aligns with our city’s values."

The groundbreaking ceremony included FSS staff, Fagron management, community leaders, and construction partners, taking place at the site of the future expansion.

 

Wichita Mayor Lily Wu and Fagron Sterile Services US leadership break ground on major facility expansion for Wichita operations.

About Fagron Sterile Services

As a subsidiary of Fagron, a leading global company active in pharmaceutical compounding, Fagron Sterile Services US(FSS) is the only globally integrated 503B outsourcing partner, dedicated to creating supply chain resiliency and advancing patient safety. FSS provides trusted outsourcing solutions to thousands of hospitals, ambulatory surgery centers, and healthcare facilities across the US.

Committed to quality, safety, and innovation, FSS operates FDA-registered and inspected cGMP compliant facilities in Wichita, KS and Boston, MA, with a corporate office in Austin, TX. FSS plays a critical role in addressing the US drug shortage crisis, supporting the availability of high-quality sterile medications in all 50 states.

FSS’s extensive portfolio supports Critical Care, Labor and Delivery, Ophthalmics, Pain Management, Oncology, and other specialized solutions, including the only sterile LET Gel available in the market and an innovative Avastin presentation. Through its steadfast dedication to reliable medication supply, Fagron Sterile Services US empowers patient care and contributes to the overall well-being of communities nationwide.

Visit fagronsterile.com to download a product catalog, schedule a free consultation, and learn more today.

References
Sean Jones, MBA
Senior Director of Marketing at Fagron North America, with more than a decade of experience in the pharmaceutical and healthcare industries.